Regulatory axis of IL-23/IL-17 in immunopathological inflammation in patients with psoriasis - target for the most effective biological therapy
Abstract
Psoriasis is the systemic immunopathological (autoimmune) inflammatory diseases with prevailing presentation on skin. Immunopathological inflammation is characterized by abnormal functional polarization of cells both innate and specific immunity.
The loss of homeostatic regulation is the result of these processes. The critical role in the immunopathological inflammation in patients with psoriasis is given to the regulatory axis of interleukins IL-12/IL-23 and IL-23/IL-17.
Biologics targeting components of IL-23/IL-17 axis demonstrated the best clinical efficacy and could be recognized as the latest generation of biological therapy currently used in the treatment of psoriasis. Initiation and amplification phases of inflammation in psoriasis are also addressed.
